NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=150490&from=4CLASS PERIOD: August 8, 2024 to February ...

Core Viewpoint - A lawsuit has been filed against The Bancorp, Inc. (NASDAQ: TBBK) by an investor, alleging violations of securities laws related to undisclosed risks and financial reporting issues [2]. Group 1: Lawsuit Details - The lawsuit claims that The Bancorp underrepresented the significant risk of default or loss on its REBL loan portfolio [2]. - Allegations include that the company's expected credit loss methodology was insufficient, leading to a likely increase in provisions for credit losses [2]. - The plaintiff asserts there were material weaknesses in internal controls over financial reporting, and that financial statements were not approved by an independent auditor, making them unreliable [2]. Group 2: Investor Information - Shareholders who purchased shares of The Bancorp, Inc. prior to February 2024 and continue to hold them are encouraged to contact the Shareholders Foundation for options [1][3]. - The Shareholders Foundation provides services related to shareholder issues, including information on securities class actions and legal news [3].

Core Viewpoint - A class action lawsuit has been filed against Open Lending Corporation for alleged violations of federal securities laws, specifically regarding misleading statements about its risk-based pricing model and profit share revenue [1] Group 1: Lawsuit Details - The lawsuit claims that Open Lending overstated the capabilities of its risk-based pricing model and misrepresented its profit share revenue [1] - It is alleged that the company failed to disclose that loans from 2021 and 2022 were worth less than their outstanding balances [1] - Investors were misled about the underperformance of the company's vintage loans from 2023 and 2024 [1] Group 2: Shareholder Information - Shareholders who purchased Open Lending securities between February 24, 2022, and March 31, 2025, are encouraged to contact the DJS Law Group before June 30, 2025, to participate in the lawsuit [1][2]

SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA’s Oncologic Drugs Advisory Committee (“ODAC”) voted against the risk/benefit profile of UroGen’s UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”) for which no drugs are currently FDA-approved. Hagens Berman has opened an investigation in ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Open Lending Corporation regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's financial performance and risk-based pricing models [1][2]. Summary by Relevant Sections Allegations - Defendants allegedly made false statements and concealed information regarding: - Misrepresentation of the capabilities of the company's risk-based pricing models - Materially misleading statements about the company's profit share revenue - Failure to disclose that the 2021 and 2022 vintage loans were worth significantly less than their outstanding loan balances - Misrepresentation of the underperformance of the 2023 and 2024 vintage loans [1]. Class Period and Registration - The class period for the lawsuit is from February 24, 2022, to March 31, 2025 - Shareholders who purchased shares during this period are encouraged to register for the class action by June 30, 2025, to potentially be appointed as lead plaintiffs [1][2]. Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle - Participation in the case incurs no cost or obligation for shareholders [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificial deflation of Cerevel's stock price [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at this artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - The January 18, 2024 Proxy statement from Cerevel is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3] - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status [3]

LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cleveland-Cliffs Inc. ("Cleveland-Cliffs" or "the Company") (NYSE: CLF) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cleveland-Cliffs reportd its financial results for Q1 2025 on May 7, 20 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of materially false and misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations Against Sana Biotechnology - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [1]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [1]. Group 2: Class Action Participation - Shareholders who purchased shares of SANA during the class period are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: About The Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147732&from=4 CLA ...

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=147716&from=4CLASS PERIOD: October 31, 2022 ...